User: TahirAmin Topic: IP
Category: drugs :: india
Last updated: Jan 19 2018 06:48 IST RSS 2.0
 
1 to 20 of 6,122    
At AstraZeneca, fewer drug projects bring big productivity jump 19.1.2018 General News
LONDON (Reuters) - A focus on fewer diseases, together with cuts in laboratories and staff, has delivered a more than fourfold increase in research productivity at drugmaker AstraZeneca , based on one key measure of success.
Also found in: [+]
Biocon collaborates with Sandoz for next-gen biosimilars 18.1.2018 General News
Bio-pharmaceuticals firm Biocon today announced a global partnership with Sandoz, a Novartis division, to develop, manufacture and commercialise multiple biosimilars in immunology and oncology for patients worldwide. Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products and will have a cost and profit share arrangement globally, Biocon said in a statement. Worldwide commercialisation responsibilities will be divided and each company's strengths will be leveraged within specific geographies, it added. Sandoz will lead commercialisation in North America (US and Canada) and the EU including European Free Trade Association and Balkan states, while Biocon will lead commercialisation in Rest of the World including India, Russia and Commonwealth of Independent States (CIS), Biocon said. Biocon Chairperson and MD Kiran Mazumdar-Shaw said: "We are pleased to ...
Also found in: [+]
Suven Life Sciences secures product patents 18.1.2018 General News
In China and Sri Lanka
Also found in: [+]
Suven gets product patents in China, Sri Lanka 18.1.2018 General News
Suven Life Sciences has secured a product patent each from China and Sri Lanka corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. The two patents are valid through 2033 and 2032, respectively, the company said in a BSE filing. "We are pleased by the grant of these patents to Suven for our pipeline of molecules in the central nervous system (CNS) arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally," Suven Life CEO Venkat Jasti said. According to the company, the granted claims of the patents are being developed as therapeutic agents and are useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Parkinson and Schizophrenia. The stock was trading 2.42 per cent higher at Rs 209.10 on BSE.
Also found in: [+]
Panacea Biotec collaborates with Serum Institute of India 18.1.2018 General News
For manufacture and sale of fully liquid wP-IPV based Hexavalent Vaccine
Also found in: [+]
Panacea Biotec surges 10% on collaboration with Serum Institute of India 18.1.2018 Latest News
The stock surges 10% to Rs 284 after the company signed two long term agreements with Serum Institute of India and its wholly owned subsidiary, Bilthovan Biologicals BV
Also found in: [+]
Jeevan Scientific Technology announces completion of USFDA audit 17.1.2018 General News
Its clinical pharmacology centre facility receives one Form 483 observation
Also found in: [+]
Some pvt colleges allure students with misleading ads: NCDRC 17.1.2018 General News
Some private colleges allure students with misleading advertisements, the apex consumer commission said, asking a Rajasthan-based pharmacy institute to pay Rs 50,000 as compensation to a student for admitting him to an unrecognised course and awarding an invalid degree. The National Consumer Disputes Redressal Commission (NCDRC) has asked the Goyanka College of Pharmacy in Rajasthan to refund the fees paid by Anil Kumar Kumawat and asked it to pay Rs 5,000 as legal cost apart from the compensation. "It is quite often observed in our country that some of the professional institutes run by private organisations allure students by misleading advertisements and promises and collect huge fees or donations. "Most of the aspirants are kept in dark about the legality of the course," the bench comprising presiding member B C Gupta and member S M Kantikar said. While pointing out that a few institutes even admit the students without proper infrastructure and statutory permissions,
Also found in: [+]
Pharma stocks gain 17.1.2018 General News
Key benchmark indices held firm and hovered close to their intraday highs in mid-afternoon trade. At 14:20 IST, the barometer index, the S&P BSE Sensex, rose 179.27 points or 0.52% at 34,950.32. The Nifty 50 index rose 45.05 points or 0.42% at 10,745.50. The announcement of reduction in additional borrowing by the government allaying fiscal deficit concerns and expectation of big ticket changes in the Goods and Services Tax (GST) in the GST council's next meet boosted sentiment. Indices bucked weak trend in global stocks.
Also found in: [+]
JB Chemicals & Pharma's Gujarat facilities get European nod 17.1.2018 General News
J B Chemicals & Pharmaceuticals today said the Medicines Authority of Malta has granted European GMP approval to its manufacturing facilities located at Panoli, in Gujarat. "J B Chemicals & Pharmaceuticals is pleased to announce receipt of European GMP approval for its formulation facilities at Panoli, Gujarat from Medicines Authority of Malta," J B Chemicals & Pharmaceuticals said in a BSE filing. The company said this approval is valid in entire European Union. The Medicines Authority of Malta has accorded its approval to the company's manufacturing facilities for tablets, capsules, liquids for internal use and semi-solids. "This approval will not only help the company increase its product basket for this market but will also boost contract manufacturing business, which is a focused business area," it added. The stock was trading at Rs 330.20, up 3.37 per cent, on BSE.
Also found in: [+]
Sun Pharma will be watched after settling patent litigation for generic 17.1.2018 General News
Sun Pharmaceutical Industries announced that its wholly-owned subsidiaries have reached an agreement with Ironwood Pharmaceuticals, Inc. and Allergan plc (together known as the companies) to resolve the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Linzess (Linaclotide capsules) in the US. The announcement was made after market hours yesterday, 16 January 2018.
Also found in: [+]
J B Chemicals & Pharmaceuticals receives EU cGMP approval for facility at Panoli 17.1.2018 General News
From Medicines Authority of Malta
Also found in: [+]
Sun Pharma settles patent litigation with Ironwood, Allergan 16.1.2018 General News
Drug major Sun Pharma today said it has settled a patent litigation with Ironwood Pharmaceuticals Inc and Allergan plc in the US over a generic version of Linzess, a drug used to treat bowel problems. The company's wholly-owned subsidiaries have reached an agreement with Ironwood Pharmaceuticals and Allergan to resolve the patent litigation regarding submission of an abbreviated new drug application (ANDA) for a generic version of Linzess in the US, Sun Pharma said in a statement. Under the terms of settlement, Ironwood and Allergan will grant Sun Pharma subsidiaries a license to market a generic version of Linzess in the US beginning February 1, 2031 subject to USFDA approval or earlier under certain circumstances, it added. As a result of the settlement, all Hatch-Waxman litigation between Sun Pharma and both the companies, regarding the Linzess patents, will be dismissed, Sun Pharma said. The companies, however, did not share any additional details regarding the ...
Also found in: [+]
Expecting India, US, Europe to contribute over 80% sales by 2021: Glenmark 10.1.2018 General News
The company is also planning to scale up its speciality business in the US as part of its future outlook for 2021
Also found in: [+]
Medical Technology Assoc bats for tax breaks for R&D centres 8.1.2018 General News
Medical Technology Association of India (MTaI) today urged the government to provide a tax holiday to medical device R&D centres under the transfer pricing act to boost investment in innovation based in-house capabilities centres and growth of the industry. In its pre-budget recommendations for Union-Budget (2018-19), MTaI said, "The government needs to provide tax holiday to medical device R&D centres under the transfer pricing act to boost investment in high innovation based in-house capabilities centres." "We also demand tax incentives for the industry for developing global patents from India and tax deduction on income made by individuals or a company for rewards earned on patent development or licensing of patents," it said. MTaI further requested that Safe Harbour guidelines be provided for pharmaceutical companies who are manufacturing and exporting the product as contract manufacturer/ loan licensee. There are many companies dealing in manufacturing and .
Also found in: [+]
'Himachal govt to make prescribing generic drugs compulsory' 8.1.2018 General News
The new BJP government in Himachal Pradesh plans to make it compulsory for doctors of all hospitals in the state to prescribe generic drugs to patients, Health Minister Vipin Parmar said today. "The government of Himachal Pradesh shall soon bring out a law to make prescription of generic medicines compulsory in all the hospitals of the state," Parmar told a delegation of the Indian Medical Association at Nanao village near here. "Himachal will become the first state to bring out such a bill," he said. He said it is a priority of the Himachal government to provide qualitative and best medical facilities to the people. He said doctors have been instructed to prescribe generic drugs and those medicines, which are available free at the hospitals. He said if a doctor prescribes drugs other than generic, he will have to write his reasons on the prescription too. Parmar urged IMA officials to cooperate and give suggestions to improve the healthcare system.
Also found in: [+]
Govt may blacklist eight Chinese pharma firms over quality issues 7.1.2018 Latest News
The notices were issued after a special inspection team of the Drug Controller General of India inspected the eight companies in China
Also found in: [+]
Eight Chinese pharma firms may be blacklisted over quality issues 7.1.2018 Cinema-Showbiz
The Indian government has issued showcause notices to, and may soon blacklist, eight Chinese pharmaceutical companies found to be supplying poor quality raw material to drug manufacturers in this country.
Also found in: [+]
A safety net 5.1.2018 Hindu: Opinion
The Indian Patents Act protects against the evergreening of the drugs, which is a common practice by pharma giants to try to stop generic companies from producing lower priced drugs (“How India reject...
Also found in: [+]
‘Public stockholding of grains to stay’ 5.1.2018 Hindu: Business
Protected by 2014 negotiation: Prabhu
Also found in: [+]
1 to 20 of 6,122